^
    Back
    Association details:
    Biomarker:ATRX deletion
    Cancer:Glioma
    Drug:Talzenna (talazoparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Transl Oncol
    Title:

    Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity

    Excerpt:
    U251 and LN229 glioma cells...We then validated the differential PARP inhibitor sensitivity in our U251 line containing ATRX shRNA. Upon ATRX knockdown, U251 cells show sensitivity to olaparib...and BMN-673...loss of ATRX confers significant sensitivity to PARP inhibitors.
    DOI:
    https://doi.org/10.1016/j.tranon.2021.101147